Live Breaking News & Updates on மாநாடு தலைப்பு

Stay updated with breaking news from மாநாடு தலைப்பு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Penn State vs. Illinois


Penn State vs. Illinois
1:57 am
It was Conference Championship Saturday and even though their game didn’t get Penn State a Conference Title, it was a big Win for Penn State. In Penn State’s very first play, Sean Clifford finds Jahan Dotson, who finds open space and a 75 yard Touchdown. What a way to open up this game. On their next drive, Clifford fumbles on the first play. Fast forward and the Nittany Lions get the ball back. James McCourt with a 65 yard kickoff return Touchdown. Penn State putting up 12 points in 3 plays. This First Half was all Offense, with 21 points from the Fighting Illini and Dotson makes it 42 points from the Nittay Lions. Dotson had two Touchdowns before half time. ....

James Mccourt , Nittay Lions , Isiah Williams , Sean Clifford , Nittany Lions , Jahan Dotson , Conference Championship Saturday , Penn State , Conference Title , First Half , Fighting Illini , Second Half , Will Levis , Tight End Brenton Strange , ஜேம்ஸ் ம்க்கொர்ட் , இசியா வில்லியம்ஸ் , சீன் கிளிஃபோர்ட் , நித்தனி சிங்கங்கள் , ஜஹான் டாட்சன் , மாநாடு சாம்பியன்ஷிப் சனிக்கிழமை , பென் நிலை , மாநாடு தலைப்பு , முதல் பாதி , சண்டை இல்லினி , இரண்டாவது பாதி , விருப்பம் லெவிஸ் ,

TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies ...


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies .
TG Therapeutics, Inc.December 10, 2020 GMT
Both
significantly reducing
each of the
U
BLA
Thursday, December 10, 2020
ET
NEW YORK, Dec. 10, 2020 (GLOBE NEWSWIRE) TG Therapeutics, Inc. (NASDAQ: TGTX), today announced positive topline results from two global, active-controlled, Phase 3 studies, called ULTIMATE I & II, evaluating ublituximab, the Company’s investigational novel, glycoengineered anti-CD20 monoclonal antibody, compared to teriflunomide in patients with relapsing forms of multiple sclerosis (RMS). Both studies met their primary endpoint with ublituximab treatment demonstrating a statistically significant reduction in annualized relapse rate (ARR) over a 96-week period (p 0.005 in each trial). Ublituximab treatment resulted in an ARR of 0.10 ....

New York , United States , Jenna Bosco , Sclerosis International Federation , Drug Administration , National Multiple Sclerosis Society , Exchange Commission , Globe Newswire Tg Therapeutics Inc , Corporate Communications , Tg Therapeutics Inc , Thursday December , Conference Title , Tyrosine Kinase , Private Securities Litigation Reform Act , Annual Report , Vice President , Accessed October , Multiple Sclerosis International Federation , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , ஜென்னா போஸ்கோ , ஸ்க்லரோசிஸ் சர்வதேச கூட்டமைப்பு , தேசிய பல ஸ்க்லரோசிஸ் சமூகம் , பரிமாற்றம் தரகு , பெருநிறுவன தகவல்தொடர்புகள் , க் சிகிச்சை இன்க் ,